Alto Neuroscience, Inc. (NYSE:ANRO) Shares Purchased by Bank of New York Mellon Corp

Bank of New York Mellon Corp raised its holdings in Alto Neuroscience, Inc. (NYSE:ANRO) by 15.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 52,271 shares of the company’s stock after acquiring an additional 6,812 shares during the quarter. Bank of New York Mellon Corp’s holdings in Alto Neuroscience were worth $221,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. Geode Capital Management LLC raised its holdings in shares of Alto Neuroscience by 148.7% in the 3rd quarter. Geode Capital Management LLC now owns 469,988 shares of the company’s stock worth $5,378,000 after purchasing an additional 281,018 shares in the last quarter. State Street Corp grew its position in Alto Neuroscience by 123.7% in the third quarter. State Street Corp now owns 236,857 shares of the company’s stock worth $2,710,000 after buying an additional 130,985 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Alto Neuroscience by 95.3% in the third quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company’s stock valued at $13,965,000 after buying an additional 595,673 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Alto Neuroscience during the 3rd quarter valued at $124,000. Finally, Barclays PLC boosted its stake in shares of Alto Neuroscience by 872.7% during the 3rd quarter. Barclays PLC now owns 29,599 shares of the company’s stock worth $339,000 after acquiring an additional 26,556 shares in the last quarter.

Alto Neuroscience Stock Down 4.4 %

Shares of NYSE:ANRO opened at $2.31 on Friday. The firm has a 50 day simple moving average of $3.44 and a 200 day simple moving average of $5.72. Alto Neuroscience, Inc. has a 52 week low of $2.27 and a 52 week high of $17.55. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. The company has a market cap of $62.40 million and a PE ratio of -0.91.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.09. As a group, research analysts expect that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a research report on Friday, March 21st. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Alto Neuroscience presently has an average rating of “Moderate Buy” and a consensus price target of $16.75.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.